Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AbD Serotec

Published: Monday, December 17, 2012
Last Updated: Sunday, December 16, 2012
Bookmark and Share
MorphoSys to increase focus on therapeutics.

MorphoSys AG has announced that it has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostic products.

The total consideration amounts to approximately EUR 53 million and will be settled in cash.

The total consideration comprises the purchase price, compensation for cash reserves in the AbD Serotec companies in the amount of approximately EUR 5 million and a license payment for the use of the HuCAL technology in the research and diagnostic markets.

The transaction is subject to certain closing conditions, and is expected to be completed in January, 2013.

"This transaction was done to enable an increased focus on our therapeutic business segment", commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.

Dr. Moroney continued, "We are making great progress in our therapeutic antibody pipeline, which is a huge potential value driver for MorphoSys. With the sale of AbD Serotec, we will bring a laser-like focus to driving growth in this, our area of core competence."

According to the terms of the transaction, Bio-Rad Laboratories will acquire all of MorphoSys's AbD Serotec research reagent and diagnostic business, comprising the AbD Serotec segment of MorphoSys AG as well as the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc.

In addition, the transaction includes a fully paid-up, non-exclusive license agreement to use MorphoSys's HuCAL technology for diagnostic and research purposes.

"As a result of today's transaction MorphoSys will concentrate on technology and drug development. It enables us to fully dedicate our financial resources to the most significant value drivers," commented Jens Holstein, Chief Financial Officer of MorphoSys AG.

Holstein continued, "Bio-Rad provides AbD Serotec and its employees with an ideal environment in which to exploit its potential in the research and diagnostic arena."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MorphoSys Reports Results for the First Quarter of 2013
First quarter positively impacted by sale of AbD Serotec.
Friday, May 03, 2013
AbD Serotec and Merck Sign License Agreement for Use of HuCAL GOLD in Vaccine Research
Merck is granted access to HuCAL GOLD for research purposes, with the option to upgrade to MorphoSys's antibody library HuCAL PLATINUM.
Tuesday, August 09, 2011
MorphoSys Presents New Antibody Technology arYla
arYla opens up new ways to optimize therapeutic and diagnostic antibodies.
Monday, November 15, 2010
MorphoSys Receives Research Grant to Advance Anti-CD38 Cancer Program MOR202
The Company plans to explore relevant biomarkers for the anti-CD38 approach in collaboration with Munich Technical University.
Wednesday, July 07, 2010
MorphoSys Announces Clinical Milestone from Strategic Alliance
The announcement represents the second HuCAL-derived antibody to achieve this stage during the course of 2010.
Friday, July 02, 2010
MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program
MorphoSys strengthens clinical portfolio with innovative antibody in Phase 1 cancer trial.
Monday, June 28, 2010
MorphoSys Granted Further Patent on its Core Antibody Technology in Japan
The new patent covers the production and design of an antibody library based on phage display.
Friday, March 19, 2010
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Magnetic Nanoparticles May Reveal Early Traces Of Cancer
Rice University students’ computer program aids MD Anderson diagnostic initiative .
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!